Affinage

USP13

Ubiquitin carboxyl-terminal hydrolase 13 · UniProt Q92995

Length
863 aa
Mass
97.3 kDa
Annotated
2026-06-10
100 papers in source corpus 56 papers cited in narrative 56 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

USP13 is a deubiquitinase (DUB) that controls the abundance, localization, and activity of a broad array of substrates by editing ubiquitin chains, predominantly removing K48-linked chains to oppose proteasomal degradation and stabilize its targets (PMID:24270891, PMID:37311811). Mechanistically, USP13 has weak intrinsic isopeptidase activity and, unlike its paralog USP5, cannot be activated by free ubiquitin because its ZnF domain fails to bind free ubiquitin; its tandem UBA domains instead confer preferential binding to K63-linked diubiquitin (PMID:22216260). This domain architecture underlies a recurring duality: USP13 acts catalytically to deubiquitinate and stabilize many substrates, but also acts non-catalytically through its ubiquitin-binding domains, as in its regulation of the E3 ligase Siah2 and its competition with the E3 ligase TRIM31 to protect NLRP3 from ubiquitination (PMID:21659512, PMID:41004574). Through these activities USP13 sits at the intersection of several major cellular programs. In autophagy it deubiquitinates Beclin1 and, in a NEDD4-1-scaffolded complex, removes K48 chains from VPS34/PIK3C3 to promote autophagy initiation, and stabilizes ATG5 and the selective-autophagy receptor p62/SQSTM1 (PMID:21962518, PMID:32101753, PMID:37776917, PMID:36528756, PMID:39216303). In the DNA damage response it is phosphorylated by ATM, localizes to double-strand breaks, and deubiquitinates RAP80 to support BRCA1 focus formation, while also stabilizing TopBP1 to enable ATR activation under replication stress (PMID:28569838, PMID:33592542). In innate immunity and inflammation it deconjugates ubiquitin from STING to restrain TBK1 recruitment and antiviral signaling, and regulates NLRP3 inflammasome activity in both K48- and K63-dependent and non-catalytic modes (PMID:28534493, PMID:41004574, PMID:41206387). Across cancers USP13 stabilizes oncogenic and metabolic regulators including PTEN, c-Myc, MCL1, cyclin D1, the metabolic enzymes ACLY and OGDH, and fatty acid synthase, thereby influencing proliferation, metabolic reprogramming, and EMT (PMID:24270891, PMID:27923907, PMID:27892457, PMID:29335437, PMID:37311811, PMID:35898882). USP13 activity and stability are themselves regulated by upstream phosphorylation (ATM, CK2 at Thr122, Aurora B at Ser114), by JNK-dependent proteasomal degradation following LPS, and by TDP-43-dependent splicing (PMID:28569838, PMID:32772043, PMID:36612196, PMID:33169399, PMID:40202498).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 1998 Low

    Established USP13 as a gene encoding a putative isopeptidase paralogous to USP5, raising the question of whether shared architecture implied shared or divergent substrate specificity.

    Evidence Genomic sequencing and comparative organization on chromosome 3q26

    PMID:9841226

    Open questions at the time
    • No functional or catalytic assay
    • Substrate specificity unaddressed
  2. 2011 High

    Defined the biochemical basis of USP13's catalytic behavior, answering why a USP5-like enzyme has weak activity and distinct chain preference.

    Evidence In vitro DUB assays on K48/K63 polyubiquitin, NMR of the ZnF domain, and domain-swap mutagenesis

    PMID:22216260

    Open questions at the time
    • Does not explain how individual physiological substrates are selected
    • In-cell relevance of K63 preference for specific targets unresolved
  3. 2011 High

    Revealed that USP13 can act through its ubiquitin-binding domains rather than catalysis, establishing a non-catalytic mode that protects an E3 ligase (Siah2) from autodegradation.

    Evidence Catalytic vs. ubiquitin-binding domain mutants in stability assays

    PMID:21659512

    Open questions at the time
    • Generality of the non-catalytic mode across substrates not yet known
    • Structural detail of UBA-substrate engagement unresolved
  4. 2011 High

    Connected USP13 to autophagy and melanoma growth, identifying Beclin1/Vps34 and MITF as stabilized substrates and linking USP13 to tumor maintenance.

    Evidence Spautin-1 inhibitor, shRNA DUB screen, protein stability assays, and xenografts

    PMID:21811243 PMID:21962518

    Open questions at the time
    • Direct enzymatic deubiquitination of Beclin1 by USP13 not fully separated from USP10
    • Chain linkage on MITF not defined
  5. 2013 High

    Identified PTEN as a USP13 substrate, establishing USP13 as a tumor-suppressive regulator of PI3K/AKT signaling and glycolysis.

    Evidence DUB screen, Co-IP, in vitro deubiquitination, knockdown/overexpression, and xenografts

    PMID:24270891

    Open questions at the time
    • Ubiquitin chain linkage on PTEN not specified
    • Counteracting E3 ligase not identified
  6. 2014 High

    Placed USP13 in ER-associated degradation, showing it maintains the Bag6 chaperone complex by deubiquitinating Ubl4A downstream of gp78.

    Evidence Co-IP, in vitro ubiquitination/deubiquitination, and ERAD substrate assays

    PMID:24424410

    Open questions at the time
    • Quantitative contribution to global ERAD flux unresolved
    • Regulation of the gp78-USP13 association unknown
  7. 2016 High

    Extended USP13 to oncogenic stabilization and metabolic reprogramming by identifying c-Myc, ACLY, and OGDH as substrates governing stem-cell self-renewal and central carbon metabolism.

    Evidence Co-IP, ubiquitination/deubiquitination assays, T58A-Myc rescue, metabolic readouts, and in vivo models

    PMID:27892457 PMID:27923907

    Open questions at the time
    • Whether metabolic enzyme stabilization is a primary or secondary effect of altered signaling unresolved
  8. 2017 High

    Defined USP13 roles in the DNA damage response and innate immunity, showing ATM phosphorylation directs it to DSBs to deubiquitinate RAP80, while it deconjugates STING to dampen antiviral signaling.

    Evidence Phosphorylation and DSB-localization assays, deubiquitination assays, and USP13 KO mice/viral challenge

    PMID:28534493 PMID:28569838

    Open questions at the time
    • ATM phosphosite on USP13 not mapped
    • Chain linkage removed from STING in the antiviral context not defined
  9. 2018 High

    Established USP13 as a regulator of apoptotic threshold and replication-stress signaling by stabilizing MCL1 and supporting cohesin/mitotic dynamics, with therapeutic relevance to BH3 mimetics.

    Evidence siRNA screen, Co-IP, deubiquitination, CRISPR KO, BH3 mimetic sensitivity, and affinity purification/MS

    PMID:29335437 PMID:33334891

    Open questions at the time
    • Paradoxical requirement for both deubiquitination and ubiquitination of cohesin mechanistically unresolved
    • Direct vs. indirect MCL1 chain editing not fully separated
  10. 2020 High

    Resolved how USP13 promotes autophagy initiation, showing NEDD4-1 auto-ubiquitination scaffolds USP13 to remove K48 chains from VPS34 at K419.

    Evidence Co-IP, linkage- and site-specific deubiquitination, and KO functional autophagy assays

    PMID:32101753

    Open questions at the time
    • Signals controlling NEDD4-1 auto-ubiquitination upstream unresolved
  11. 2020 Medium

    Showed USP13 protein levels are dynamically controlled by phosphorylation (CK2/Aurora B) and LPS-induced JNK-dependent proteasomal degradation, framing USP13 as a regulated, not constitutive, node.

    Evidence Kinase and phospho-mutant assays, cycloheximide chase, inhibitor studies, and catalytic-mutant controls

    PMID:32772043 PMID:33169399 PMID:36612196

    Open questions at the time
    • Cross-talk among the multiple phospho-inputs unresolved
    • JNK-dependent degradation E3 ligase not identified
  12. 2021 Medium

    Broadened the substrate landscape to EMT, cell cycle, and replication-stress factors (Snail, cyclin D1 precursors, TopBP1, mutant EGFR), including peptidase-independent stabilization of mutant EGFR.

    Evidence Co-IP, deubiquitination assays, MG132 rescue, Cbl epistasis, and migration/invasion assays

    PMID:33210294 PMID:33592542 PMID:34872023

    Open questions at the time
    • Determinants of mutant- vs. wild-type EGFR selectivity unresolved
    • Catalytic vs. non-catalytic contribution varies by substrate and is incompletely mapped
  13. 2023 Medium

    Demonstrated linkage-resolved substrate editing, with K48-specific stabilization of cyclin D1, METTL3, and Twist1 and K63-specific editing of beta-catenin, tying USP13 to defined oncogenic transcriptional and epitranscriptomic programs.

    Evidence K48/K63-specific deubiquitination assays, site-directed mutagenesis, m6A profiling, and in vivo metastasis/growth models

    PMID:36732432 PMID:37151889 PMID:37311811 PMID:38043062

    Open questions at the time
    • How a single DUB switches between K48 and K63 specificity on different substrates unresolved
  14. 2023 Medium

    Connected USP13 to redox and selective-autophagy regulation via p62/SQSTM1, Beclin1, and the NRF2/KEAP1 axis, positioning it as a determinant of ferroptosis sensitivity and antioxidant gene expression.

    Evidence Site-specific (p62 K7) mutagenesis, autophagy flux assays, KEAP1/NRF2 readouts, and aged KO mouse fibrosis models

    PMID:36150040 PMID:37776917

    Open questions at the time
    • Tissue-specific balance between autophagy promotion and degradation outcomes unresolved
  15. 2025 High

    Established context-dependent, often non-catalytic control of inflammasome and immune signaling, with USP13 either stabilizing NLRP3 (by competing with TRIM31) or restraining it via K63 editing at K557, and restraining JAK-STAT via SOCS1.

    Evidence Site-specific K192/K496/K557 ubiquitination assays, DUB-dead mutants, KO macrophages/cardiomyocytes in vivo, and immune phenotyping

    PMID:41004574 PMID:41206387 PMID:42000926

    Open questions at the time
    • Cell-type determinants that switch USP13 between activating and inhibiting NLRP3 unresolved
  16. 2025 Medium

    Defined cardioprotective and tissue-homeostasis roles in vivo through deubiquitination of STAT1, ALDOA, GRP78, and SMAD3, and a non-canonical STING route to autolysosomal degradation, supported by tissue-specific KO and AAV9 rescue.

    Evidence Interactome/MS, site-specific deubiquitination, cardiomyocyte/intestinal/HSC-specific KO, and AAV9 therapeutic overexpression in disease models

    PMID:40487656 PMID:40593642 PMID:40679368 PMID:40719972 PMID:41496210

    Open questions at the time
    • Whether STING is stabilized or routed for degradation is context-dependent and mechanistically unreconciled across tissues
  17. 2025 Medium

    Linked USP13 expression and splicing to upstream transcriptional and RNA-regulatory control (HIF-1alpha, YY1, RREB1/KRAS, FOXO4, TDP-43), and to TDP-43 proteinopathy as a disease modifier.

    Evidence ChIP/promoter/EMSA assays, m6A/IGF2BP2 stabilization, and TDP-43 knockdown splicing and ALS-model phenotyping

    PMID:38043062 PMID:40202498 PMID:40319251 PMID:40876694 PMID:41330897 PMID:41371952

    Open questions at the time
    • Direct causal role of USP13 splicing changes in human neurodegeneration unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved what governs USP13's choice between catalytic and ubiquitin-binding-only modes and between K48 vs K63 chain editing on a per-substrate basis, and how a single DUB produces opposing outcomes (stabilization vs. degradation, pro- vs. anti-inflammatory) in different tissues.
  • No unifying structural model of substrate/linkage selection
  • Tissue-specific cofactors directing opposing outcomes not identified
  • No catalytic-domain co-structure with a physiological substrate

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 8 GO:0016787 hydrolase activity 4 GO:0098772 molecular function regulator activity 3
Localization
GO:0005634 nucleus 3 GO:0005829 cytosol 3 GO:0000228 nuclear chromosome 2
Pathway
R-HSA-168256 Immune System 5 R-HSA-9612973 Autophagy 5 R-HSA-1430728 Metabolism 4 R-HSA-1640170 Cell Cycle 3 R-HSA-392499 Metabolism of proteins 3 R-HSA-73894 DNA Repair 3
Partners
ACLYBECLIN1MCL1NLRP3PTENRAP80STINGVPS34
Complex memberships
Bag6 chaperone complex (gp78-associated)NEDD4-1–USP13 complex

Evidence

Reading pass · 56 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2011 USP13 deubiquitinates Beclin1, and Beclin1 in turn controls the protein stabilities of USP10 and USP13 by regulating their deubiquitinating activities. USP13 (with USP10) targets the Beclin1 subunit of Vps34 PI3 kinase complexes; inhibition of USP13 promotes degradation of Vps34 complexes. Because USP10 mediates deubiquitination of p53, Beclin1 regulation of USP13/USP10 activity connects p53 levels to autophagy. Small-molecule inhibitor (spautin-1) targeting USP10/USP13, Co-IP, protein stability assays in cells Cell High 21962518
2011 USP13 deubiquitinates MITF (microphthalmia-associated transcription factor), stabilizing MITF protein levels. Knockdown of USP13 leads to loss of MITF protein without affecting mRNA, demonstrating post-translational stabilization. USP13 modulates MITF downstream target gene expression and is required for melanoma growth. shRNA library screen against DUBs, USP13 knockdown, protein stability assays, in vivo nude mouse xenograft Nature communications High 21811243
2011 USP13 regulates Siah2 E3 ubiquitin ligase stability and activity via its ubiquitin-binding domains (UBA and UBP domains) rather than its catalytic isopeptidase activity. USP13 binds ubiquitinated Siah2 and prevents its autodegradation, but this effect is abolished by mutations in ubiquitin-binding sequences, not catalytic site mutations. Consequently, USP13 attenuates Siah2's ability to target its substrates (PHD3, Spry2). Overexpression, shRNA knockdown, site-directed mutagenesis of catalytic and ubiquitin-binding domains, protein stability assays The Journal of biological chemistry High 21659512
2011 USP13 exhibits weak deubiquitinating activity preferring K63-linked polyubiquitin, operating in a non-activation manner. The ZnF domain of USP13, unlike that of its paralog USP5, cannot bind free ubiquitin and therefore USP13 cannot be activated by free ubiquitin. Substitution of the USP13 ZnF domain with the USP5 ZnF domain confers catalytic activation. The tandem UBA domains preferentially bind K63-linked diubiquitin, explaining the substrate preference. Biochemical DUB assays with K48/K63 polyubiquitin substrates, NMR structural analysis of ZnF domain, domain-swap mutagenesis, cell-based CD3δ regulation assay PloS one High 22216260
2013 USP13 physically associates with PTEN and deubiquitinates PTEN to stabilize its protein levels. Loss of USP13 in breast cancer cells promotes AKT phosphorylation, proliferation, anchorage-independent growth, and glycolysis through downregulation of PTEN. DUB screen (30 DUBs) for PTEN physical association, Co-IP, in vitro deubiquitination assay, USP13 knockdown/overexpression, in vivo xenograft Nature cell biology High 24270891
2014 USP13 is a gp78-associated deubiquitinase that removes ubiquitin conjugates from Ubl4A (a component of the Bag6 chaperone complex), preventing gp78-mediated polyubiquitination and irreversible proteolytic inactivation of Bag6. This maintains the functionality of the Bag6 chaperone complex in ERAD, sharpening substrate specificity for the gp78 E3 ligase. Co-IP identifying USP13 association with gp78, in vitro ubiquitination/deubiquitination assays, cell-based ERAD substrate degradation assays eLife High 24424410
2016 USP13 deubiquitinates and stabilizes c-Myc by antagonizing FBXL14-mediated ubiquitination of c-Myc, thereby maintaining glioblastoma stem cell (GSC) self-renewal and tumorigenic potential. Depletion of USP13 promotes c-Myc ubiquitination and degradation. The ubiquitin-insensitive T58A-c-Myc mutant rescues the effects of USP13 disruption or FBXL14 overexpression. Co-IP, ubiquitination assays, USP13 knockdown/overexpression, T58A-c-Myc rescue experiments, in vivo tumor growth assays The Journal of experimental medicine High 27923907
2016 USP13 specifically deubiquitinates and upregulates ATP citrate lyase (ACLY) and oxoglutarate dehydrogenase (OGDH), two key metabolic enzymes determining mitochondrial respiration, glutaminolysis, and fatty acid synthesis in ovarian cancer cells. Co-IP, deubiquitination assays, knockdown/overexpression with metabolic readouts, in vivo ovarian tumor models Nature communications High 27892457
2017 USP13 interacts with STING and deconjugates polyubiquitin chains from STING, preventing the recruitment of TBK1 to the STING signaling complex and thereby negatively regulating antiviral responses. USP13 knockout mice are more resistant to lethal HSV-1 infection. Co-IP identifying USP13-STING interaction, in vitro deubiquitination assay, USP13 KD/KO cells and knockout mice, IRF3/NF-κB activation assays, viral replication assays Nature communications High 28534493
2017 USP13 is phosphorylated by ATM kinase following DNA damage, which facilitates its localization to DNA double-strand breaks (DSBs). USP13 then deubiquitinates RAP80, promoting RAP80 recruitment and proper DNA damage response (DDR) including BRCA1 complex foci formation. Co-IP, phosphorylation assays, DSB localization by immunofluorescence, RAP80 ubiquitination assays, USP13 depletion/inhibition sensitivity assays in ovarian cancer cells Nature communications High 28569838
2018 USP13 interacts with and stabilizes MCL1 via deubiquitination, regulating MCL1 turnover in lung and ovarian cancer cells. CRISPR/Cas9-mediated USP13 depletion reduces MCL1 protein abundance and increases sensitivity to BH3 mimetic inhibitors. Unbiased siRNA screen, Co-IP, deubiquitination assay, CRISPR/Cas9 KO, in vivo xenograft, BH3 mimetic sensitivity assays Nature communications High 29335437
2018 USP5 and USP13 are recruited to heat-induced stress granules via their deubiquitylating activities. Depletion of USP13 elevates ubiquitin chain levels in stress granules, accelerates their assembly, and markedly impairs their disassembly after heat stress removal. USP13 regulates stress granule dynamics by deubiquitylating protein-conjugated ubiquitin chains. Immunofluorescence recruitment assay, siRNA knockdown, ubiquitin chain level measurements, stress granule assembly/disassembly kinetics Journal of cell science Medium 29567855
2020 The E3 ubiquitin ligase NEDD4-1 undergoes K29-linked auto-ubiquitination at K1279, which serves as a scaffold to recruit USP13. The resulting NEDD4-1–USP13 complex deubiquitinates VPS34/PIK3C3 by removing K48-linked poly-ubiquitin chains at K419, stabilizing VPS34 and promoting autophagy initiation. Co-IP, deubiquitination assay, ubiquitin linkage-specific analysis, NEDD4-1 and USP13 KO cell lines, autophagosome formation assays Cell reports High 32101753
2020 USP13 interacts with cohesin and its ubiquitin-binding domains (UBA1/2) are required for this interaction. The interaction occurs specifically in the soluble nuclear fraction and preferentially during DNA replication. USP13 is paradoxically required for both deubiquitination and ubiquitination of cohesin subunits, and is required for dissociation of cohesin from chromatin as cells transit through mitosis, but is dispensable for sister chromatid cohesion. Endogenous dual-affinity purification + mass spectrometry, Co-IP in multiple cell lines, domain mapping (UBA1/2 mutants), CRISPR KO, cell fractionation, mitotic chromosome spreads The Journal of biological chemistry High 33334891
2020 USP13 associates with Aurora B kinase and stabilizes Aurora B, especially before mitotic entry. Aurora B-mediated phosphorylation of USP13 at Serine 114 promotes their association. USP13 instigates Aurora B deubiquitination and/or protects it from degradation in a manner that may be partially non-catalytic. Modulation of USP13 levels/activity affects unperturbed cell-cycle progression. Co-IP, phosphorylation assays, USP13 gain/loss-of-function, protein stability assays, cell cycle analysis Oncogene Medium 32772043
2020 USP13 deubiquitinates and stabilizes Smad4 in lung fibroblast cells. USP13 and Smad4 co-localize in the cytoplasm and co-translocate to the nucleus in response to TGF-β1. USP13 deficiency in mice reduces extracellular matrix (ECM) protein levels, demonstrating a role in ECM expression regulation through Smad4 stabilization. Co-IP, pulse-chase protein stability assay, USP13 KO mice, overexpression/knockdown, immunofluorescence co-localization Translational research Medium 32434004
2019 USP13 deubiquitinates and stabilizes IL-1R8/Sigirr, an anti-inflammatory receptor. USP13 levels directly correlate with IL-1R8/Sigirr; knockdown increases IL-1R8/Sigirr poly-ubiquitination and degradation, enhancing TLR4 signaling and cytokine release. USP13-deficient mice are highly susceptible to LPS- and Pseudomonas-induced lung injury, and IL-1R8/Sigirr overexpression rescues the inflammatory phenotype. Receptor ligation chase model, Co-IP, poly-ubiquitination assay, USP13 KO mice, acute lung injury model, IL-1R8/Sigirr overexpression rescue EBioMedicine High 31204278
2021 USP13 binds to TopBP1 and stabilizes it via deubiquitination, facilitating ATR activation in response to replication stress. Depletion of USP13 impedes ATR activation and hypersensitizes cells to replication stress-inducing agents. Co-IP, deubiquitination assay, USP13 knockdown, ATR activation assays, replication stress sensitivity assays DNA repair Medium 33592542
2021 USP13 interacts with Snail transcription factor and deubiquitinates it, stabilizing Snail protein and promoting EMT and metastasis in gastric cancer. USP13 knockdown promotes Snail degradation blockable by proteasome inhibitor MG132; Snail knockdown blocks USP13-induced migration. Co-IP, deubiquitination assay, proteasome inhibitor rescue, knockdown/overexpression, migration/invasion assays Pathology, research and practice Medium 34872023
2021 USP13 deubiquitinates and stabilizes Mcl-1 in cervical cancer cells. USP13 depletion reduces Mcl-1 expression, inhibits cell proliferation, and increases sensitivity to BH3 mimetic ABT-263. Co-IP, deubiquitination assay, USP13 knockdown, Mcl-1 stability assays, BH3 mimetic sensitivity Oncogene Medium 33627786
2021 USP13 deubiquitinates IRAK4 in macrophages. Myeloid-specific USP13 deficiency increases LPS-induced pro-inflammatory responses and worsens septic symptoms in mice, which can be rescued by IRAK4 inhibitor co-administration. USP13 myeloid-specific KO mice (USP13MKO), Co-IP/deubiquitination assay, IRAK4 inhibitor rescue, BMDM inflammatory assays, sepsis mouse model Microbes and infection Medium 34298177
2022 USP13 binds ZHX2 (Zinc Fingers And Homeoboxes 2) and promotes ZHX2 deubiquitination and protein stability in an enzymatically dependent manner. USP13 depletion leads to ZHX2 downregulation and decreased ccRCC cell proliferation. DUB cDNA library binding screen, Co-IP, deubiquitination assay, USP13 depletion, 2D/3D growth assays, in vivo tumor growth PNAS Medium 36037364
2022 N6-methyladenosine (m6A) modification by METTL3 (read by IGF2BP2) stabilizes USP13 mRNA. USP13 protein interacts with ATG5 and stabilizes ATG5 via deubiquitination; PAK1 kinase-mediated phosphorylation of ATG5 enhances its interaction with USP13. This USP13-ATG5 axis enhances autophagy and imatinib resistance in GIST cells. Co-IP, deubiquitination assay, PAK1 phosphorylation assay, m6A-seq, USP13 inhibitor (spautin-1) + 3-MA treatment in xenograft models Cell death and differentiation Medium 36528756
2022 Casein kinase 2 (CK2) directly interacts with USP13 and phosphorylates it at Thr122, promoting the stability of USP13 protein. Thr122 phosphorylation is important for ovarian cancer cell proliferation. Co-IP, kinase assay, phospho-specific detection, phosphorylation-deficient and phosphomimetic mutants, cell proliferation assays Cancers Medium 36612196
2022 USP13 modulates the stability of the APC/C adaptor CDH1. USP13 binds CDH1 and its overexpression increases CDH1 levels while depletion decreases them, establishing a USP13-CDH1-Aurora B regulatory axis for cell cycle progression. Co-IP, Western blot after USP13 overexpression/siRNA/shRNA, cell cycle analysis Molecular biology reports Low 35397714
2023 USP13 deubiquitinates and stabilizes cyclin D1 by physically binding to its N-terminal domain and removing K48-linked (but not K63-linked) polyubiquitin chains, promoting G1/S cell cycle progression and proliferation in gastric cancer cells. Co-IP, deubiquitination assay with K48/K63 ubiquitin mutants, USP13 KO/overexpression, cell cycle analysis, in vivo xenograft Oncogene High 37311811
2023 USP13 directly binds p62/SQSTM1 and removes ubiquitin at Lys7 (K7) of the PB1 domain. This deubiquitination enhances p62 protein stability and facilitates p62 oligomerization, resulting in increased selective autophagy and degradation of Keap1, thereby promoting Nrf2 activation and antioxidant gene expression. Co-IP, site-directed mutagenesis (K7), ubiquitination assay, autophagy flux assays, Keap1/Nrf2 pathway readouts Free radical biology & medicine Medium 37776917
2023 USP13 interacts with and deubiquitinates METTL3 at K488 by removing K48-linked ubiquitin chains, stabilizing METTL3 and increasing global m6A abundance in osteosarcoma cells, which promotes ATG5 mRNA stability and autophagy-associated malignancy. Co-IP, deubiquitination assay with K48 ubiquitin mutants, RNA-seq, m6A-IP sequencing, USP13 inhibitor in xenograft International journal of biological sciences Medium 37151889
2023 USP13 interacts with Twist1 and specifically cleaves K48-linked polyubiquitin chains from Twist1 induced by FBXL14, stabilizing Twist1 and promoting breast cancer cell migration and invasion. Twist1 in turn inhibits USP13 transcriptional activity, forming a negative feedback loop. Co-IP, GST pulldown, deubiquitination assay with K48-specific ubiquitin, USP13 KD/OE, migration/invasion and in vivo lung metastasis assays, luciferase reporter for USP13 promoter Cellular oncology Medium 36732432
2023 KRAS drives expression of USP13 through the transcription factor RREB1. Elevated USP13 removes K63-linked polyubiquitination of β-catenin at lysine 508, enhancing binding of β-catenin to TCF4 and promoting KRAS-mutant NSCLC metastasis. ChIP/reporter assays for RREB1-USP13 axis, Co-IP, K63-specific deubiquitination assay, K508 site mutation, metastasis assays in vitro and in vivo Cell reports Medium 38043062
2023 USP13 interacts with and deubiquitinates SARM1 (axon degeneration executor). USP13 deubiquitination of SARM1 increases the inhibitory interaction between SARM1's N-terminal ARM domain and C-terminal TIR domain, suppressing SARM1 activation and delaying injury-induced axon degeneration. Enzyme-dead USP13 fails to protect injured axons. Proximity labeling/proteomics to identify SARM1 interactome, overexpression of WT vs. enzyme-dead USP13, domain interaction assays, axon degeneration assays Life medicine Medium 39872893
2023 USP13 deubiquitinates Beclin 1 (distinct from the earlier finding that Beclin1 regulates USP13). In aged Usp13-deficient mice, impaired Beclin 1 deubiquitination leads to insufficient autophagic activity and increased vulnerability to bleomycin-induced lung fibrosis. USP13-deficient aged mice, Beclin 1 deubiquitination assay, Beclin 1 overexpression rescue, bleomycin fibrosis model American journal of respiratory cell and molecular biology Medium 36150040
2020 USP13 protein is degraded in response to LPS in Kupffer cells via the ubiquitin-proteasome system. LPS increases USP13 polyubiquitination and reduces its protein stability (not transcription). Inhibition of c-Jun N-terminal kinase (JNK) attenuates USP13 degradation, indicating JNK-dependent new protein synthesis is necessary for USP13 degradation. A catalytically inactive USP13 shows similar degradation, indicating the mechanism is activity-independent. LPS treatment, proteasome/lysosome inhibitor experiments, JNK inhibitor, cycloheximide chase, catalytic mutant USP13 Journal of cellular physiology Medium 33169399
2022 USP13 deubiquitinates and stabilizes ATG5 in gastrointestinal stromal tumor cells (also confirmed in AML). PAK1-mediated phosphorylation of ATG5 enhances the ATG5-USP13 interaction. Co-IP, deubiquitination assay, PAK1 inhibition, USP13 knockdown, autophagy flux and tumor growth assays Cell death and differentiation / Tissue & cell Medium 36528756 39216303
2024 USP13 interacts with and deubiquitinates NFE2L2/NRF2, upregulating NRF2 protein levels. In KRAS-mutant lung adenocarcinoma, USP13 depletion promotes an autophagy-to-ferroptosis switch through the NRF2-SQSTM1/p62-KEAP1 axis. DUB screen (85 DUBs), Co-IP, deubiquitination assay, USP13 KD in vitro and xenograft, autophagy/ferroptosis markers Autophagy Medium 39360581
2024 USP13 interacts with TAK1 (transforming growth factor β-activated kinase 1) and inhibits K63-linked ubiquitination and phosphorylation of TAK1, thereby dampening downstream inflammatory pathways (NF-κB) and promoting insulin signaling in the context of NAFLD. Co-IP, ubiquitination assay (K63-specific), TAK1 inhibitor rescue, USP13 overexpression/KO mice, NAFLD models Journal of translational medicine Medium 39033101
2024 USP13 deubiquitinates ATG7 (autophagy-related 7) by preventing its degradation, stabilizing ATG7 protein and promoting ferroptosis in chicken granulosa cells. USP13 overexpression/knockdown, Co-IP, deubiquitination assay, ferroptosis markers (GSH, lipid peroxidation, iron) Poultry science Low 39214053
2023 USP13 interacts with FASN (fatty acid synthase) and enhances FASN protein stability, with this USP13-FASN axis required for SCLC cancer stem cell maintenance and lipogenesis. Effect requires enzymatic activity of USP13 (inactive mutant cannot rescue). Co-IP, protein stability assay, WT vs. inactive USP13 rescue, sphere formation assay, in vivo tumor growth Frontiers in oncology Medium 35898882
2021 USP13 selectively stabilizes mutant EGFR (but not wild-type EGFR) in a peptidase-independent manner by counteracting the action of Cbl family E3 ubiquitin ligases. Unbiased high-throughput siRNA screen, USP13 KD, Cbl ligase functional assays, mutant vs. WT EGFR stability, in vitro and in vivo sensitivity assays International journal of cancer Medium 33210294
2025 USP13 stabilizes NLRP3 independently of its deubiquitinating enzyme activity by competing with E3 ligase TRIM31 to interact with NLRP3, preventing TRIM31-mediated ubiquitination of NLRP3 at K192 and K496, thereby inhibiting proteasomal degradation of NLRP3 and promoting NLRP3 inflammasome assembly and activation. Co-IP, ubiquitination assay with site-specific NLRP3 K192/K496 mutants, USP13 KO in human and mouse macrophages, DUB-dead mutant analysis, inflammasome activation readouts, peritonitis mouse model Science advances High 41004574
2025 USP13 deubiquitinates STAT1, reducing its degradation. In cardiomyocytes, USP13 promotes STAT1-targeted Nppb gene transcription and enhances mitochondrial function. Cardiomyocyte-specific Usp13 knockout aggravates pressure overload-induced cardiac hypertrophy, while AAV9-mediated USP13 overexpression has therapeutic effects. Interactome analysis identifying STAT1 as substrate, Co-IP, deubiquitination assay, cardiomyocyte-specific KO mice (TAC/Ang II models), AAV9 overexpression Nature communications High 40593642
2025 USP13 deubiquitinates the stimulator of interferon genes (STING) and promotes its autolysosome-related degradation (rather than stabilization), alleviating cardiomyocyte inflammation in doxorubicin-induced cardiotoxicity. Cardiomyocyte-specific USP13 KO exacerbates cardiotoxicity while overexpression mitigates it. RNA-seq, Co-IP, deubiquitination assay, cardiomyocyte-specific KO mice, AAV9 overexpression, autophagy flux assays Acta pharmaceutica Sinica. B Medium 40487656
2025 USP13 deubiquitinates SMAD3 by removing K48-linked ubiquitin chains at K13 of SMAD3's MH2 domain (USP13 C345 is the catalytic cysteine involved), stabilizing SMAD3 and enhancing its transcriptional activity for profibrotic genes, thereby promoting hepatic stellate cell activation and liver fibrosis. Co-IP/MS substrate identification, domain mapping (MH2 domain), K13 site-specific ubiquitination assay, C345 catalytic mutant, HSC-specific AAV-mediated KD, CCl4 and BDL fibrosis mouse models Hepatology international Medium 40719972
2025 USP13 deubiquitinates WWP1 E3 ligase by removing K29- and K48-linked polyubiquitin chains, stabilizing WWP1 via the ubiquitin-proteasome pathway. The transcription factor YY1 activates USP13 transcription and also upregulates WWP1 through USP13. Co-IP, mass spectrometry, ubiquitination assay with K29/K48-specific chains, ChIP and luciferase assay for YY1-USP13 promoter interaction, in vivo xenograft Cellular & molecular biology letters Medium 40319251
2025 USP13 deubiquitinates NLRP3 at K557 by removing K63-linked ubiquitin chains, inhibiting NLRP3-ASC interaction and ASC polymerization, thereby inhibiting NLRP3 inflammasome activation and alleviating pyroptosis in cardiomyocytes in diabetic cardiomyopathy. Co-precipitation + LC-MS/MS substrate identification, K557 site-specific ubiquitination assay, K63-specific ubiquitin chains, cardiomyocyte-specific KO mice (type I and II diabetic), AAV9 overexpression, NLRP3-deficient rescue Cell death and differentiation High 41206387
2025 USP13 stabilizes ACLY (ATP citrate lyase) via K48-specific deubiquitination at K726, preventing proteasomal degradation. Under hypoxia, HIF-1α transcriptionally upregulates USP13 by binding its promoter, creating a hypoxia-USP13-ACLY axis that drives ferroptosis resistance and immune evasion in HCC. Co-IP, K48-specific deubiquitination assay at K726, HIF-1α ChIP/promoter assay, USP13 inhibitor (2-Met) in PDOs and xenograft, scRNA-seq, flow cytometry Cell death discovery Medium 41330897
2025 USP13 interacts with ALDOA (fructose-bisphosphate aldolase A) via its USP domain and regulates K48-linked deubiquitination and stability of ALDOA at K13, preventing its proteasomal degradation and thereby restraining ferroptosis in cardiomyocytes following myocardial infarction. Co-IP, K48-specific ubiquitination assay at K13, USP13-deficient mice + cardiac-specific AAV9 overexpression, MI surgery model, ferroptosis markers Redox biology Medium 41496210
2025 USP13 interacts with and stabilizes SOCS1 by mediating K63-linked deubiquitination of SOCS1, thereby restraining excessive JAK-STAT pathway activation. USP13 knockout promotes αPD-1 resistance in CRC tumors and reduces CD8+ T-cell infiltration. Co-IP, K63-specific ubiquitination assay, USP13 KO syngeneic mouse model, flow cytometry for CD8+ T cells, JAK-STAT pathway readouts Oncogene Medium 42000926
2025 USP13 interacts with and deubiquitinates PARP1, stabilizing PARP1 via the ubiquitin-proteasome pathway and promoting PARP1-mediated DNA damage repair in multiple myeloma cells. Mass spectrometry, Co-IP, in vitro ubiquitination assay, USP13 KD/OE, PARP1 stability assay, MM xenograft and patient-derived tumor xenograft models Basic & clinical pharmacology & toxicology Medium 40151951
2025 TDP-43 regulates USP13 RNA splicing; TDP-43 knockdown induces aberrant splicing of USP13 and blocks USP13 rhythmic expression, enhancing BMAL1 ubiquitination and disrupting circadian clock gene expression. TDP-43 knockdown in vivo and in vitro, RNA splicing analysis of USP13, BMAL1 ubiquitination assay, circadian wheel behavior tests The Journal of cell biology Medium 40202498
2025 USP13 regulates MDM2 protein by targeting its K63-linked polyubiquitination. Overexpression of USP13 reduces MDM2 levels (degradation prevented by MG132) and promotes cell senescence; knockdown increases MDM2 levels. This places USP13 in a lung aging/senescence pathway. USP13 KO mice, KD/OE in human cell lines, MDM2 stability assay with MG132, K63-specific ubiquitination assay, β-galactosidase senescence assay Life sciences Medium 37634814
2025 USP13 interacts with GRP78 and removes K63-linked ubiquitin at K327 of GRP78, attenuating ER stress-induced apoptosis and maintaining intestinal barrier integrity. Intestinal epithelial-specific USP13 KO exacerbates DSS-induced colitis. Co-IP, site-specific K63 deubiquitination assay at K327, intestinal epithelial Usp13 KO mice, AAV9 rescue, DSS colitis model, apoptosis/ER stress markers Advanced science Medium 40679368
2026 USP13 interacts with KDM3A histone demethylase and specifically removes K63-linked ubiquitin chains from KDM3A; this indirectly promotes K48-linked polyubiquitination-dependent proteasomal degradation of KDM3A in the cytoplasm, inhibiting bladder cancer metastasis. Co-IP, K63/K48-specific ubiquitination assay, USP13 KD, bladder-injected liver metastasis xenograft model Oncogene Medium 41872693
2025 USP13 stabilizes CMAS (cytidine monophosphate N-acetylneuraminic acid synthetase) by specifically cleaving K48-linked polyubiquitin chains from CMAS, enhancing melanogenic capacity. The transcription factor FOXO4 represses USP13 expression through direct promoter interaction, establishing a FOXO4-USP13-CMAS regulatory axis in melanogenesis. Proteome-ubiquitinome analysis of USP13-overexpressing melanocytes, Co-IP, K48-specific deubiquitination assay, FOXO4 luciferase reporter + EMSA Cellular signalling Medium 40876694
2026 USP13 knockdown reduces insoluble TDP-43 levels and reduces cell death in primary rat motor neurons; knockdown also improves locomotor deficits in C. elegans ALS models, identifying USP13 as a modifier of TDP-43-induced aggregation and cytotoxicity. Inducible mutant TDP-43 HEK293 model, discovery proteomics via RAD23A KD, USP13 KD in HEK293 and primary rat neurons, TDP-43 solubility assay, C. elegans locomotor assay The Journal of neuroscience Medium 41371952
1998 ISOT-3 (USP13) was identified as a novel isopeptidase T gene on human chromosome 3q26.2–q26.3, showing 54.8% amino acid identity to ISOT-1 (USP5). The exonic organization is highly conserved with ISOT-1, with USP13 having significantly larger introns (gene ≥90 kb vs 15 kb for ISOT-1), suggesting common ancestry but potentially different substrate specificities. Genomic sequencing, Northern blot analysis of tissue expression, comparative genomic organization Gene Low 9841226

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 693 21962518
2013 Deubiquitylation and stabilization of PTEN by USP13. Nature cell biology 181 24270891
2017 USP13 negatively regulates antiviral responses by deubiquitinating STING. Nature communications 176 28534493
2016 Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. The Journal of experimental medicine 129 27923907
2018 Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nature communications 115 29335437
2016 Amplification of USP13 drives ovarian cancer metabolism. Nature communications 107 27892457
2017 USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response. Nature communications 100 28569838
2011 Regulation of MITF stability by the USP13 deubiquitinase. Nature communications 89 21811243
2019 USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer. Journal of experimental & clinical cancer research : CR 87 31200745
2014 USP13 antagonizes gp78 to maintain functionality of a chaperone in ER-associated degradation. eLife 67 24424410
2018 Deubiquitylases USP5 and USP13 are recruited to and regulate heat-induced stress granules through their deubiquitylating activities. Journal of cell science 64 29567855
2020 Auto-ubiquitination of NEDD4-1 Recruits USP13 to Facilitate Autophagy through Deubiquitinating VPS34. Cell reports 62 32101753
2011 USP13 enzyme regulates Siah2 ligase stability and activity via noncatalytic ubiquitin-binding domains. The Journal of biological chemistry 57 21659512
2011 Domain analysis reveals that a deubiquitinating enzyme USP13 performs non-activating catalysis for Lys63-linked polyubiquitin. PloS one 50 22216260
2016 Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals. Oncogene 49 27869170
2014 MicroRNA‑135b regulates the stability of PTEN and promotes glycolysis by targeting USP13 in human colorectal cancers. Oncology reports 48 25571954
2022 USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer. Proceedings of the National Academy of Sciences of the United States of America 47 36037364
2022 N6-methyladenosine-modified USP13 induces pro-survival autophagy and imatinib resistance via regulating the stabilization of autophagy-related protein 5 in gastrointestinal stromal tumors. Cell death and differentiation 46 36528756
2021 The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer. Oncogene 45 33627786
2015 Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis. Respiratory research 44 26453058
2023 USP13 deubiquitinates and stabilizes cyclin D1 to promote gastric cancer cell cycle progression and cell proliferation. Oncogene 40 37311811
2020 USP13 mediates PTEN to ameliorate osteoarthritis by restraining oxidative stress, apoptosis and inflammation via AKT-dependent manner. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 40 33378983
2019 The deubiquitinase USP13 stabilizes the anti-inflammatory receptor IL-1R8/Sigirr to suppress lung inflammation. EBioMedicine 39 31204278
2019 USP13 serves as a tumor suppressor via the PTEN/AKT pathway in oral squamous cell carcinoma. Cancer management and research 37 31802942
2023 Deubiquitinase USP13 regulates glycolytic reprogramming and progression in osteosarcoma by stabilizing METTL3/m6A/ATG5 axis. International journal of biological sciences 32 37151889
2019 Amplification of USP13 drives non-small cell lung cancer progression mediated by AKT/MAPK signaling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 32 30986623
2022 USP13: Multiple Functions and Target Inhibition. Frontiers in cell and developmental biology 31 35445009
2023 USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity. Molecular cancer 29 38093367
2022 Role of USP13 in physiology and diseases. Frontiers in molecular biosciences 28 36188217
2020 USP13 controls the stability of Aurora B impacting progression through the cell cycle. Oncogene 27 32772043
2024 USP13 facilitates a ferroptosis-to-autophagy switch by activation of the NFE2L2/NRF2-SQSTM1/p62-KEAP1 axis dependent on the KRAS signaling pathway. Autophagy 26 39360581
2023 Exosomal USP13 derived from microvascular endothelial cells regulates immune microenvironment and improves functional recovery after spinal cord injury by stabilizing IκBα. Cell & bioscience 25 36915206
2021 USP13 regulates the replication stress response by deubiquitinating TopBP1. DNA repair 25 33592542
2021 Deubiquitinase USP13 promotes the epithelial-mesenchymal transition and metastasis in gastric cancer by maintaining Snail protein. Pathology, research and practice 25 34872023
2023 Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin. Cell reports 22 38043062
2020 The NEDD4-USP13 axis facilitates autophagy via deubiquitinating PIK3C3. Autophagy 22 32174250
2018 The Autophagy Inhibitor Spautin-1 Antagonizes Rescue of Mutant CFTR Through an Autophagy-Independent and USP13-Mediated Mechanism. Frontiers in pharmacology 22 30618756
1998 The genomic organization of Isopeptidase T-3 (ISOT-3), a new member of the ubiquitin specific protease family (UBP). Gene 22 9841226
2023 USP13 promotes breast cancer metastasis through FBXL14-induced Twist1 ubiquitination. Cellular oncology (Dordrecht, Netherlands) 21 36732432
2023 USP13 deubiquitinates p62/SQSTM1 to induce autophagy and Nrf2 release for activating antioxidant response genes. Free radical biology & medicine 21 37776917
2022 The Deubiquitinase USP13 Maintains Cancer Cell Stemness by Promoting FASN Stability in Small Cell Lung Cancer. Frontiers in oncology 21 35898882
2021 Targeting USP13-mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non-small cell lung cancer. International journal of cancer 21 33210294
2021 Regulatory Role of Ubiquitin Specific Protease-13 (USP13) in Misfolded Protein Clearance in Neurodegenerative Diseases. Neuroscience 18 33577955
2023 USP13 Deficiency Impairs Autophagy and Facilitates Age-related Lung Fibrosis. American journal of respiratory cell and molecular biology 16 36150040
2022 MicroRNA profiling reveals miR-145-5p inhibits goat myoblast differentiation by targeting the coding domain sequence of USP13. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 15 35635726
2022 USP13 promotes development and metastasis of high-grade serous ovarian carcinoma in a novel mouse model. Oncogene 14 35173307
2021 miR-19a-3p inhibition alleviates sepsis-induced lung injury via enhancing USP13 expression. Acta biochimica Polonica 14 33966370
2025 YY1 induced USP13 transcriptional activation drives the malignant progression of hepatocellular carcinoma by deubiquitinating WWP1. Cellular & molecular biology letters 13 40319251
2023 USP13 reduces septic mediated cardiomyocyte oxidative stress and inflammation by inducing Nrf2. Allergologia et immunopathologia 12 36916102
2020 Deubiquitinase USP13 promotes extracellular matrix expression by stabilizing Smad4 in lung fibroblast cells. Translational research : the journal of laboratory and clinical medicine 12 32434004
2023 Chloroquine Intervenes Nephrotoxicity of Nilotinib through Deubiquitinase USP13-Mediated Stabilization of Bcl-XL. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11 37452432
2025 Cardiomyocyte-derived USP13 protects hearts from hypertrophy via deubiquitinating and stabilizing STAT1 in male mice. Nature communications 10 40593642
2023 USP13 regulates cell senescence through mediating MDM2 stability. Life sciences 10 37634814
2020 Molecular profiling of immune cell-enriched Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) interacting protein USP13. Life sciences 10 32735883
2021 USP13-mediated IRAK4 deubiquitination disrupts the pathological symptoms of lipopolysaccharides-induced sepsis. Microbes and infection 9 34298177
2020 USP13 interacts with cohesin and regulates its ubiquitination in human cells. The Journal of biological chemistry 9 33334891
2024 USP13 Cooperates with MARCH8 to Inhibit Antiviral Signaling by Targeting MAVS for Autophagic Degradation in Teleost. Journal of immunology (Baltimore, Md. : 1950) 7 38214605
2024 LncRNA FRMD6-AS1/miR-491-5p/USP13 pathway attenuated ferroptosis and contributed to liver fibrosis. Environmental toxicology 7 38558500
2024 USP13 ameliorates nonalcoholic fatty liver disease through inhibiting the activation of TAK1. Journal of translational medicine 7 39033101
2024 USP13 regulates ferroptosis in chicken follicle granulosa cells by deubiquitinating ATG7. Poultry science 7 39214053
2024 The carcinogenesis of esophageal squamous cell cancer is positively regulated by USP13 through WISP1 deubiquitination. BioFactors (Oxford, England) 7 39468941
2023 Deubiquitination of SARM1 by USP13 regulates SARM1 activation and axon degeneration. Life medicine 7 39872893
2020 Lipopolysaccharide reduces USP13 stability through c-Jun N-terminal kinase activation in Kupffer cells. Journal of cellular physiology 7 33169399
2025 Deubiquitinase USP13 alleviates doxorubicin-induced cardiotoxicity through promoting the autophagy-mediated degradation of STING. Acta pharmaceutica Sinica. B 6 40487656
2025 Intestinal Epithelial-Derived USP13 Alleviates Colonic Inflammation by Suppressing GRP78-mediated Endoplasmic Reticulum Stress. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 6 40679368
2022 USP13 genetics and expression in a family with thyroid cancer. Endocrine 6 35583846
2022 CK2-Mediated Phosphorylation Upregulates the Stability of USP13 and Promotes Ovarian Cancer Cell Proliferation. Cancers 6 36612196
2025 USP13: A therapeutic target for combating tumorigenesis and antitumor therapy resistance. International journal of biological macromolecules 4 39900156
2025 USP13 stabilizes NLRP3 to facilitate inflammasome activation by preventing TRIM31-mediated NLRP3 ubiquitination and degradation. Science advances 4 41004574
2022 USP13 modulates the stability of the APC/C adaptor CDH1. Molecular biology reports 4 35397714
2025 Rhythmic TDP-43 affects RNA splicing of USP13, resulting in alteration of BMAL1 ubiquitination. The Journal of cell biology 3 40202498
2025 USP13 Suppresses Colorectal Cancer Angiogenesis by Downregulating VEGFA Expression through Inhibition of the PTEN-AKT Pathway. Oncology research 3 40746889
2025 USP13 ameliorates diabetic cardiomyopathy via deubiquitinating NLRP3 and inhibiting pyroptosis in cardiomyocytes. Cell death and differentiation 3 41206387
2021 USP13 Deficiency Aggravates Cigarette-smoke-induced Alveolar Space Enlargement. Cell biochemistry and biophysics 3 34032995
2026 Ubiquitin Proteasome System Components, RAD23A and USP13, Modulate TDP-43 Solubility and Neuronal Toxicity. The Journal of neuroscience : the official journal of the Society for Neuroscience 2 41371952
2025 USP13 overexpression in BMSCs enhances anti-apoptotic ability and guards against methylprednisolone-induced osteonecrosis in rats. Stem cells (Dayton, Ohio) 2 39460600
2024 USP13 promotes acute myeloid leukemia cell proliferation and autophagy by promoting ATG5. Tissue & cell 2 39216303
2024 USP13 ameliorates metabolic dysfunction-associated steatohepatitis through targeting PTEN. Life sciences 2 39571890
2025 USP13 Facilitates the Proliferation of Hepatocellular Carcinoma Cells by Reducing K48/63-Linked Polyubiquitination and Degradation of PRPF6. Journal of cellular and molecular medicine 1 40208227
2025 USP13 promotes hepatic stellate cells activation and aggravates liver fibrosis through deubiquitinating SMAD3. Hepatology international 1 40719972
2025 USP13 mediates resistance to Ibrutinib in diffuse large B-cell lymphoma via augmenting FHL1 stabilization. American journal of cancer research 1 40814378
2025 USP13 depletion sensitizes colorectal cancer cells to necroptosis by destabilizing cIAP2 proteins. Cell death and differentiation 1 41125793
2025 ASNS Regulates H2O2-Induced Senescence, Oxidative Stress, and Glucose Metabolism in ARPE-19 Cells by Modulating USP13 Expression. BioFactors (Oxford, England) 1 41293996
2025 Hypoxia-induced USP13 expression drives ferroptosis resistance and tumor immune evasion in hepatocellular carcinoma through the stabilization of ACLY. Cell death discovery 1 41330897
2024 USP13 inhibition exacerbates mitochondrial dysfunction and acute kidney injury by acting on MCL-1. Biochimica et biophysica acta. Molecular basis of disease 1 39608596
2026 USP13 facilitates pressure overload induced vascular remodeling and phenotypic transition of VSMCs via deubiquitinating Beclin-1. Cell death discovery 0 41484066
2026 Non-classic deubiquitinase USP13 inhibits bladder cancer metastasis through destabilizing cytoplasmic KDM3A. Oncogene 0 41872693
2026 USP13 stabilizes SOCS1 to reverse αPD-1 resistance in MSI-H colorectal cancer. Oncogene 0 42000926
2026 USP13 promotes enzalutamide resistance by catalyzing depolyubiquitination of PCMT1 in prostate cancer. Cell death & disease 0 42056074
2026 USP13 Downregulation Distinguishes Malignant from Adjacent Non-Neoplastic Prostate Tissue and Suggests Altered PTEN-Related Regulatory Pathways in a Korean Cohort. Life (Basel, Switzerland) 0 42195268
2025 Bruceine A Inhibits Cell Proliferation by Targeting the USP13/PARP1 Signalling Pathway in Multiple Myeloma. Basic & clinical pharmacology & toxicology 0 40151951
2025 Non-classic deubiquitinase USP13 inhibits bladder cancer metastasis through destabilizing cytoplasmic KDM3A. Oncogene 0 40253486
2025 Ubiquitinome profiling identifies USP13-CMAS axis as critical regulator of hair follicular melanogenesis via K48-linked polyubiquitination. Cellular signalling 0 40876694
2025 Microvascular Endothelial Cell-Derived Exosomes Decrease Osteoclastogenesis by Restraining Osteoclast Ferroptosis through the USP13/NRF2/GPX4 Pathway. Critical reviews in immunology 0 41213070
2025 USP13 exacerbates the malignant progression of cervical cancer by inhibiting ECT2 ubiquitination and degradation. Reproductive biology 0 41223669
2025 METTL3-mediated m6A modification of circCDYL promotes gastric cancer progression by acting as miR-378a-5p sponge to regulate USP13 expression. Cellular signalling 0 41237839
2025 USP13 promotes colorectal cancer progression by deubiquitinating and stabilizing HIF-1α. Cell communication and signaling : CCS 0 41272808
2025 USP13 dictates Ran turnover and vulnerability to ferroptosis in diffuse large B cell lymphoma (DLBCL). Cell death & disease 0 41315297
2025 USP13-Mediated selective autophagy of eIF5B promotes pathological cardiac hypertrophy. Cellular and molecular life sciences : CMLS 0 41400714
2025 USP13 ameliorates myocardial infarction injury by inhibiting ferroptosis via stabilizing ALDOA. Redox biology 0 41496210

Missed literature

Know a paper Affinage missed for USP13? Flag it for the maintainers and the community.

No submissions yet.